RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
+0.84%Margins
Gross margin
84.4%
EBITDA margin
-621.7%
EBIT margin
-678.0%
Net margin
-621.7%
FCF margin
-604.1%
-136.8%
Return on equity
-107.1%
Return on assets
-145.0%
Return on invested capital
0.16x
Asset turnover
-$11.9M
Cash from operations
$0.21
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026